Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that sales of antipsychotics and anticonvulsants for the bipolar drug market will reach $2.6 billion in 2011; this figure will represent nearly 90% of the total bipolar disorder drug market.

(Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION )

"Growth in the on- and off-label use of antipsychotics and anticonvulsants will be the key market driver for the bipolar disorder drug market from 2001 through 2011," said Timothy Gasperoni, Ph.D., analyst at Decision Resources. "These agents will expand the range of therapeutic options for the short- and long-term treatment of manic and depressive symptoms -- particularly for the estimated 30-50% of patients who are unable to tolerate or fail to respond to lithium, the current standard of care."

The new Pharmacor study entitled Bipolar Disorder also finds that Bristol- Myers Squibb's Abilify (aripiprazole) will spur market growth.

"Despite its limited regulatory approval (i.e., for acute mania only) and its patent expiration in all markets in 2009, we expect Abilify to garner more than 11% of the bipolar disorder market in 2011," continued Dr. Gasperoni.

Disease Background-Bipolar Disorder

Bipolar disorder is a chronic and debilitating psychiatric illness characterized by recurrent episodes of aberrant mood. Mood episodes vary in duration among patients and feature symptoms of mania, depression, hypomania (a less severe form of mania), or a mixture of both depression and mania. Although more than 5 million people in the seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) are afflicted with bipolar disorder, drug development for this indication has remained relatively stagnant.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Bipolar Disorder is a Psychiatric Disorders study.

About Decision Resources

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company provides strategic information services, and assesses international pharmaceutical and health care industry trends. Visit Decision Resources at www.decisionresources.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,
emarshall@dresources.com

Launches of Novel Bone-Forming Agents, Such as Eli Lilly's Forteo, Will Play a Major Role in Driving the Growth of the Osteoporosis Market

View Now